Business
Amgen Announces The Outcome Of The Recommended Public Cash Offer To The Shareholders Of Nuevolution, Declares The Offer Unconditional And Completes The Offer
THOUSAND OAKS, Calif., July 8, 2019 /PRNewswire/ -- The Offer is not being made, and this press release may not be distributed, directly or indirectly, in or
About this update from Amgen Inc.
[{"type":"text","content":"THOUSAND OAKS, Calif., July 8, 2019 /PRNewswire/ -- \nThe Offer is not being made, and this press release may not be distributed, directly or indirectly, in or into, nor will any tender of shares be accepted from or on behalf of holders in, Australia, Canada, Hong Kong, Japan, New Zealand or South Africa, or any other jurisdiction in which the making of the Offer, the distribution of this press release or the acceptance of any tender of shares would contravene applicable laws or regulations or require further offer documents, filings or other measures in addition to those required under Swedish law. \nShareholders in the United States should refer to the section entitled \"Important Information to U.S. Shareholders\" at the end of this press release. \nOn 22 May 2019 at 08:00 CEST, Amgen Inc. (\"Amgen\") (NASDAQ:AMGN) announced a recommended public cash offer to the shareholders of Nuevolution AB (publ) (\"Nuevolution\") to tender all their shares in Nuevolution to Amgen (the \"Offer\") for SEK 32.50 per share in cash (the \"Offer Price\").(1) Nuevolution's shares are listed on Nasdaq Stockholm, Small Cap.\nAt the end of the Offer acceptance period on 4 July 2019, the Offer had been accepted by shareholders representing a total of 48,313,224 shares and votes in Nuevolution, corresponding to approximately 97.6% of the total number of issued and outstanding shares and votes in Nuevolution(2) (approximately 88.4% of the total number of shares and votes on a fully diluted basis(3)). As communicated in the Offer announcement and the offer document describing the Offer, which was published on 12 June 2019 (the \"Offer Document\"), the Offer did not include warrants issued by Nuevolution to participants under the incentive programs implemented by Nuevolution (\"Warrants\"), and Amgen provided Warrant holders an opportunity to sell all their Warrants to Amgen outside of the Offer (the \"Warrant Offer\"). The Warrant Offer has been accepted by Warrant holders representing all 5,109,254 Warrants allotted under the programs, corresponding to 5,109,254 shares and votes in Nuevolution, if exercised (approximately 9.4% of the total number of shares and votes on a fully diluted basis).\nIn total, the securities tendered by shareholders and Warrant holders into the Offer and the Warrant Offer, respectively, correspond to approximately 97.8% of ...